Provided by Tiger Trade Technology Pte. Ltd.

KT Corp

18.94
+0.23001.23%
Post-market: 18.940.00000.00%19:30 EDT
Volume:2.05M
Turnover:38.71M
Market Cap:9.02B
PE:10.46
High:18.97
Open:18.91
Low:18.60
Close:18.71
52wk High:24.58
52wk Low:17.13
Shares:476.00M
Float Shares:422.00M
Volume Ratio:1.45
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.81
EPS(LYR):2.46
ROE:7.15%
ROA:2.69%
PB:0.63
PE(LYR):7.69

Loading ...

Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis

TIPRANKS
·
Aug 06

Morgan Stanley Predicts 36% Rally for South Korean Markets After Recent Rout

Trading Random
·
Aug 03

JTEKT Corp Sees FY Net Y50.00b

Dow Jones
·
Jul 31

South Korea's Privacy Regulator Fines KT KRW54 Billion for Data Breach

MT Newswires Live
·
Jul 30

YKT Corp Sees 1H Parent Pretax Y270.00m

Dow Jones
·
Jul 24

Kintor Pharma-B Sees Shareholding Increase by KT Corp's Investment Arm

Deep News
·
Jul 22

KT to Donate KRW53 Billion to Employee Welfare Fund

MT Newswires Live
·
Jul 15

KT Sets July 29 Record Date for Quarterly Dividend

TIPRANKS
·
Jul 15

KT Corporation Moves to Reacquire Treasury Shares Tied to Long-Term Incentives

TIPRANKS
·
Jul 15

KT Declares Quarterly Cash Dividend Payout

MT Newswires Live
·
Jul 14

SK Telecom and KT to Lead 17.2 Billion Won Government-Backed Hyper-AI Networks Project

MT Newswires Live
·
Jul 14

Market Chatter: KT to Invest KRW18 Trillion to Transform into AI Platform Company

MT Newswires Live
·
Jul 07

Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed?

Simply Wall St.
·
Jul 01

Kymera Therapeutics Advances KT-621 Development With Phase 2b Enrollment Completion

MT Newswires Live
·
Jun 25

Korea Exchange Activated the KOSPI "Sidecar" Temporary Trading-Halt Mechanism. SK Hynix Soared 10%; Samsung Electronics Jumped over 5%

Tiger Newspress
·
Jun 25

Korean Chip Stocks Hit by Profit-Taking; Indexes Trigger Circuit Breakers

Tiger Newspress
·
Jun 23

Why Kymera Therapeutics (KYMR) Is Up 16.6% After Positive KT-621 Phase 1 Japanese Data

Simply Wall St.
·
Jun 16

Kintor Pharma-B Reports Positive Interim Safety Data for KT-939 and Initiates New Cosmetic Ingredient Registration

Stock News
·
Jun 10

KT Corporation Details April–May 2026 Share Buybacks Under Repurchase Trust

TIPRANKS
·
Jun 10

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

GlobeNewswire
·
Jun 08